CLINICAL TRIALS PROFILE FOR BENICAR HCT

All Clinical Trials for BENICAR HCT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00122447 ↗	Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	Completed	Daiichi Sankyo Inc.	N/A	2005-05-01	The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗	Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	Completed	Daiichi Sankyo, Inc.	N/A	2005-05-01	The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗	Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	Completed	National Center for Research Resources (NCRR)	N/A	2005-05-01	The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗	Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	2005-05-01	The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗	Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	Completed	Emory University	N/A	2005-05-01	The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.

Clinical Trial Conditions for BENICAR HCT

Condition Name

Condition Name for BENICAR HCT
Intervention	Trials
Hypertension	5
Healthy	4
Essential Hypertension	2
Healthy Subjects	2

Condition MeSH

Condition MeSH for BENICAR HCT
Intervention	Trials
Hypertension	7
Essential Hypertension	2
Obesity	1
Inflammation	1

Clinical Trial Locations for BENICAR HCT

Trials by Country

Trials by Country for BENICAR HCT
Location	Trials
United States	118
Mexico	5
Chile	4
China	2
Peru	1

Trials by US State

Trials by US State for BENICAR HCT
Location	Trials
Florida	5
California	5
North Dakota	5
New York	5
Texas	4

Clinical Trial Progress for BENICAR HCT

Clinical Trial Phase

Clinical Trial Phase for BENICAR HCT
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2	1

Clinical Trial Status

Clinical Trial Status for BENICAR HCT
Clinical Trial Phase	Trials
Completed	15
Not yet recruiting	1
Unknown status	1

Clinical Trial Sponsors for BENICAR HCT

Sponsor Name

Sponsor Name for BENICAR HCT
Sponsor	Trials
Daiichi Sankyo, Inc.	4
Mylan Pharmaceuticals	4
Daiichi Sankyo Inc.	4

Sponsor Type

Sponsor Type for BENICAR HCT
Sponsor	Trials
Industry	18
Other	4
NIH	3